CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has released additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer. Pourhassan says representatives from its lab called him crying, revealing the patient's tumor had shrunk. Pourhassan says data from the first patient enrolled show no detectable circulating tumor cells (CTC) in the peripheral blood with additional reductions in CCR5 expression on cancer-associated cells at eight weeks.
Full interview: CytoDyn reveals positive data on metastatic triple-negative breast cancer trial
Quick facts: CytoDyn Inc.
Price: 2.92 USD
Market Cap: $1.66 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE